Illinois Municipal Retirement Fund increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 15.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,772 shares of the medical research company’s stock after buying an additional 6,359 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Edwards Lifesciences were worth $4,037,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of EW. Bahl & Gaynor LLC boosted its holdings in shares of Edwards Lifesciences by 87.3% during the third quarter. Bahl & Gaynor LLC now owns 9,547 shares of the medical research company’s stock worth $824,000 after purchasing an additional 4,449 shares during the period. AMG National Trust Bank increased its stake in Edwards Lifesciences by 6.1% in the 3rd quarter. AMG National Trust Bank now owns 80,054 shares of the medical research company’s stock valued at $6,910,000 after buying an additional 4,582 shares during the period. Lido Advisors LLC lifted its position in Edwards Lifesciences by 5.2% in the 3rd quarter. Lido Advisors LLC now owns 34,192 shares of the medical research company’s stock worth $2,951,000 after buying an additional 1,691 shares in the last quarter. Csenge Advisory Group lifted its position in Edwards Lifesciences by 127.8% in the 3rd quarter. Csenge Advisory Group now owns 14,437 shares of the medical research company’s stock worth $1,246,000 after buying an additional 8,099 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $397,000. 79.46% of the stock is owned by institutional investors and hedge funds.
Edwards Lifesciences Trading Up 0.0%
Edwards Lifesciences stock opened at $107.16 on Monday. Edwards Lifesciences Corporation has a one year low of $74.66 and a one year high of $107.69. The company’s fifty day moving average price is $90.42 and its two-hundred day moving average price is $86.32. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.60 and a quick ratio of 3.86. The company has a market capitalization of $61.62 billion, a price-to-earnings ratio of 60.54, a PEG ratio of 2.86 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. The company had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms have recently commented on EW. Citigroup boosted their price target on shares of Edwards Lifesciences from $110.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Deutsche Bank set a $104.00 price objective on Edwards Lifesciences in a research report on Tuesday, October 27th. Raymond James Financial boosted their target price on Edwards Lifesciences from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Finally, Barclays boosted their price target on Edwards Lifesciences from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $109.56.
Check Out Our Latest Stock Analysis on Edwards Lifesciences
Insider Buying and Selling
In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $104.25, for a total transaction of $64,530.75. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $4,173,544.50. This represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 53,945 shares of company stock valued at $5,498,306 over the last 90 days. 0.31% of the stock is currently owned by insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
See Also
- Five stocks we like better than Edwards Lifesciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
